Gajendran, Chandru
Fukui, Shoichi
Sadhu, Naveen M.
Zainuddin, Mohammed
Rajagopal, Sridharan
Gosu, Ramachandraiah
Gutch, Sarah
Fukui, Saeko
Sheehy, Casey E.
Chu, Long
Vishwakarma, Santosh
Jeyaraj, D. A.
Hallur, Gurulingappa
Wagner, Denisa D.
Sivanandhan, Dhanalakshmi
Article History
Received: 19 October 2022
Accepted: 20 February 2023
First Online: 23 February 2023
Competing interests
: D.S, C.G, NS.M, Z.M, R.G and S.R are employees of Jubilant therapeutics Inc. GH, J.D.A and SV are employees of Jubilant Biosys Ltd. The specific roles of all the authors are articulated in the ‘author contributions’ section. we confirm that “This does not alter our adherence to Scientific Reports policies on sharing data and materials.” D.S and S.R. are inventors on one and two patents respectively; covering JBI-589 and related compounds and their use in the treatment of disease/disorder mediated by PAD4. The other authors mentioned in this paper declare no competing interests.